Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04526704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Lead sponsor
Daiichi Sankyo
Phase
Phase 4
Overall status
Completed
Start date
October 20, 2020
Completion date
July 7, 2023
Enrollment
32 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

tenosynovial giant cell tumor